| Title |
Enzalutamide for patients with metastatic castration-resistant prostate cancer
|
|---|---|
| Published in |
OncoTargets and therapy, April 2015
|
| DOI | 10.2147/ott.s80488 |
| Pubmed ID | |
| Authors |
Wijdan H Ramadan, Wissam K Kabbara, Hiba S Al Basiouni Al Masri |
| Abstract |
To review and evaluate current literature on the US Food and Drug Administration (FDA)-approved drug enzalutamide (XTANDI(®)) in metastatic castration-resistant prostate cancer. Literature search was done through PubMed using the terms enzalutamide, MDV3100, abiraterone, and castration-resistant prostate cancer. Data from FDA product labels were also used. Recent and relevant studies were included in the review. Collected clinical trials were screened and evaluated. Enzalutamide is an androgen receptor (AR) inhibitor with high selectivity and affinity to the AR. It was approved by the FDA to treat metastatic castration-resistant prostate cancer in patients previously treated with docetaxel, after a Phase III trial (AFFIRM) that showed a 4.8-month survival benefit in this population. Recently, the FDA expanded the approval of enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC) who did not receive chemotherapy. Moreover, enzalutamide is shown to be associated with an acceptable safety profile. Enzalutamide has been shown to be both safe and effective in improving overall survival in metastatic castration-resistant prostate cancer postchemotherapy with docetaxel and as a first line treatment before initiation of chemotherapy. However, additional studies and head-to-head trials are needed. |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 12% |
| Student > Bachelor | 5 | 12% |
| Student > Postgraduate | 4 | 10% |
| Researcher | 3 | 7% |
| Student > Ph. D. Student | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 18 | 44% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
| Agricultural and Biological Sciences | 2 | 5% |
| Mathematics | 1 | 2% |
| Immunology and Microbiology | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 20 | 49% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2023.
All research outputs
#2,864,005
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#82
of 3,016 outputs
Outputs of similar age
#36,157
of 279,170 outputs
Outputs of similar age from OncoTargets and therapy
#3
of 37 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,170 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.